EMD Serono, the U.S. division of Merck KGaA, is parting ways with an undisclosed number of employees. The layoffs will affect research staff at the company’s offices in Durham, North Carolina.
All entries for: Endocrinology
November 4, 2025
Rhythm Pharmaceuticals
Neutral Outlook
Boston, MA
201-500 employees
Most significantly, in August 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010.
Disease Area: Endocrinology, Metabolic Diseases, Multiple, Rare Diseases
Drug Type: Small Molecule
November 4, 2025
Vertex Pharmaceuticals
Neutral Outlook
Providence, RI
5,001-10,000 employees
We cannot, however, predict how changes in the law, including through the Inflation Reduction Act of 2022 and passage of state laws (e.g., transparency laws and prescription drug affordability boards), will affect our ability to negotiate successfully with third-party payors and distribute our products.
Disease Area: Endocrinology, Hematology, Multiple, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
November 3, 2025
Rhythm Pharmaceuticals
Negative Outlook
Boston, MA
201-500 employees
IMCIVREE is not currently reimbursed under Medicare Part D, but if we were to be reimbursed under Medicare Part D in the future, the reimbursement amount will be impacted by the 10 and 20 percent discounts under the IRA’s new discounting program. We anticipate that these increased discounts could impact IMCIVREE revenues, while also having an industry-wide impact on the cost of Part D drugs. The impact on IMCIVREE revenues could be offset because the IRA’s redesign of certain Part D components, some of which went into effect in 2024, resulted in an increase in the number of patients able to afford this therapy. The amount of the offset, if any, is inherently uncertain and difficult to predict.
Disease Area: Endocrinology, Metabolic Diseases, Multiple, Rare Diseases
Drug Type: Small Molecule
October 28, 2025
Neurocrine Biosciences Inc
Negative Outlook
San Diego, CA
1,001-5,000 employees
Enacted healthcare reform, drug pricing measures and other recent legislative initiatives, including the Inflation Reduction Act of 2022 (IRA), could adversely affect our business.
Disease Area: Endocrinology, Multiple, Neurological Diseases, Psychiatry
Drug Type: Biologic, Small Molecule
October 10, 2025
Ferring Pharmaceuticals
Layoffs
Saint-Prex, Switzerland
5,001-10,000 employees
Privately held Ferring Pharmaceuticals will part ways with up to 500 employees across its global operations in a bid to “sharpen” its strategic focus and gain “flexibility” as a company. The layoffs will mean an approximately 7% headcount reduction.
Disease Area: Endocrinology, Gastrointestinal, Hematology, Oncology
Drug Type: Biologic, Small Molecule
August 14, 2025
Spruce Biosciences
Neutral Outlook
South San Francisco, CA
1-50 employees
The Inflation Reduction Act of 2022 (“IRA”) was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges and amendments in the future. It is unclear how any such challenges and the healthcare reform measures of the second Trump administration will impact the Affordable Care Act and our business.
Disease Area: Endocrinology, Multiple, Psychiatry, Rare Diseases
Drug Type: Biologic, Small Molecule
July 30, 2025
Neurocrine Biosciences Inc
Neutral Outlook
San Diego, CA
1,001-5,000 employees
AUSTEDO and AUSTEDO XR, marketed by Teva Pharmaceuticals Industries, have been selected for the Medicare drug negotiation program in 2025 (for initial price applicability year 2027). If the negotiation program results in a decrease in the price of AUSTEDO or AUSTEDO XR, it may result in increased competitive pressure on INGREZZA. We were notified in January 2025 that INGREZZA qualifies for the small biotech exception, which provides an exemption from selection until 2027 (for initial price applicability year 2029, pursuant to which negotiated pricing would go into effect, if selected). If negotiated for initial price applicability year 2029, we expect that the negotiated price for INGREZZA would be constrained by the “short monopoly” price ceiling and temporary price floor for small biotech drugs.
Disease Area: Endocrinology, Multiple, Neurological Diseases, Psychiatry
Drug Type: Biologic, Small Molecule
July 8, 2025
Conduit Pharmaceuticals
Negative Outlook
Naples, FL
1-50 employees
On August 16, 2022, President Biden signed into the law the Inflation Reduction Act of 2022, or the IRA. Among other things, the IRA has multiple provisions that can impact the prices of drug products that are both sold into the Medicare program and throughout the United States. Beginning in 2023, a manufacturer of drugs covered by Medicare Parts B or D must pay a rebate to the federal government if their drug product’s price increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting for payment year 2026, CMS will negotiate drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease.
Disease Area: Endocrinology, Immune Diseases, Multiple, Rare Diseases
Drug Type: Small Molecule
June 12, 2025
Vertex Pharmaceuticals
Layoffs
Providence, RI
5,001-10,000 employees
Just months after shelving its cell therapy–device combo for type 1 diabetes, Vertex Pharmaceuticals is parting ways with 140 employees, according to a Worker Adjustment and Retraining Notification letter dated June 6. The layoffs will heavily focus on the company’s Rhode Island operations, where 125 employees will be affected, as per the state’s WARN posting. There, Vertex is consolidating its three Providence sites, which currently form somewhat of an “integrated campus” in the city, into just one location, as per the WARN letter. “We presently expect this action to be permanent,” wrote Camilo Cobos, the biotech’s vice president of human resources.
Disease Area: Endocrinology, Hematology, Multiple, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule